80 related articles for article (PubMed ID: 14584275)
1. [Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer].
Okubo S; Kurebayashi J; Sonoo H; Hirono M; Nomura N; Udagawa K; Yamamoto Y; Ikeda M; Nakashima K; Tanaka K
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1441-5. PubMed ID: 14584275
[TBL] [Abstract][Full Text] [Related]
2. Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.
Shigeoka Y; Itoh K; Igarashi T; Ishizawa K; Saeki T; Fujii H; Minami H; Imoto S; Sasaki Y
Jpn J Clin Oncol; 2001 Aug; 31(8):370-4. PubMed ID: 11574629
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.
Perez EA; Hillman DW; Mailliard JA; Ingle JN; Ryan JM; Fitch TR; Rowland KM; Kardinal CG; Krook JE; Kugler JW; Dakhil SR
J Clin Oncol; 2004 Jul; 22(14):2849-55. PubMed ID: 15254052
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
Zelek L; Cottu P; Tubiana-Hulin M; Vannetzel JM; Chollet P; Misset JL; Chouaki N; Marty M; Gamelin E; Culine S; Dieras V; Mackenzie S; Spielmann M
J Clin Oncol; 2002 May; 20(10):2551-8. PubMed ID: 12011135
[TBL] [Abstract][Full Text] [Related]
6. [Retrospective analysis on efficacy and toxicity of paclitaxel-containing treatments in patients with advanced or recurrent breast cancer].
Hirono M; Kurebayashi J; Sonoo H; Nomura N; Okubo S; Udagawa K; Yamamoto Y; Ikeda M; Nakashima K; Tanaka K
Gan To Kagaku Ryoho; 2004 May; 31(5):723-7. PubMed ID: 15170980
[TBL] [Abstract][Full Text] [Related]
7. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
8. [A pilot study of irinotecan hydrochloride for metastatic breast cancer--efficacy as a salvage therapy].
Ikeda H; Koshiba R
Gan To Kagaku Ryoho; 2000 May; 27(5):723-7. PubMed ID: 10832441
[TBL] [Abstract][Full Text] [Related]
9. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
10. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.
Matsumoto K; Katsumata N; Yamanaka Y; Yonemori K; Kohno T; Shimizu C; Andoh M; Fujiwara Y
Gynecol Oncol; 2006 Feb; 100(2):412-6. PubMed ID: 16298422
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
Poon D; Chowbay B; Cheung YB; Leong SS; Tan EH
Cancer; 2005 Feb; 103(3):576-81. PubMed ID: 15612023
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
15. [Two cases of postoperative local skin recurrence of breast cancer successfully treated with chemotherapy of irinotecan hydrochloride (CPT-11)].
Enomoto K; Amano S; Sakurai K; Negishi N
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1782-5. PubMed ID: 16315940
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
17. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Ramos M; González-Ageitos A; Amenedo M; González-Quintas A; Gamazo JL; Togores P; Losada G; Almanza C; Romero C; Gómez-Martín C
J Chemother; 2003 Apr; 15(2):192-7. PubMed ID: 12797398
[TBL] [Abstract][Full Text] [Related]
18. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis.
Sanli UA; Karabulut B; Uslu R; Korkut M; Goker E
Med Princ Pract; 2006; 15(4):288-92. PubMed ID: 16763396
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Hayashi H; Tsurutani J; Satoh T; Masuda N; Okamoto W; Morinaga R; Terashima M; Miyazaki M; Okamoto I; Nishida Y; Tominaga S; Tokunaga Y; Yamaguchi M; Sakamoto J; Nakayama T; Nakagawa K
Breast Cancer; 2013 Apr; 20(2):131-6. PubMed ID: 22124996
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
